ATNX stock forecast
Our latest prediction for Athenex, Inc.'s stock price was made on the Dec. 24, 2019 when the stock price was at 14.54$.
In the short term (2weeks), ATNX's stock price should underperform the market by -3.56%. During that period the price should oscillate between -9.73% and +11.23%.
In the medium term (3months), ATNX's stock price should underperform the market by -8.75%. During that period the price should oscillate between -39.23% and +23.12%.Get email alerts
About Athenex, Inc.
Athenex, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of novel therapies for the treatment of cancer.It operates through the following segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The Oncology Innovation Platform segment involves in discovery and development of cancer supportive therapies. The Global Supply Chain Platform segment consists of manufacturing and marketing of API, medical devices, and clinical products. The Commercial Platform segment engages in manufacturing and selling of commercial pharmaceutical products. The company was founded by Lyn M. Dyster and David G. Hangauer in November 2003 and is headquartered in Buffalo, NY.
At the moment the company generates 88M USD in revenues.
On its last earning announcement, the company reported a loss of -1.81$ per share.
The book value per share is 1.87$
Three months stock forecastDec. 24, 2019
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|